Joint (JYNT) Competitors

$17.22
-0.44 (-2.49%)
(As of 05/17/2024 ET)

JYNT vs. EDAP, DSGN, SMTI, CDXS, IMMP, AKBA, GLUE, AXGN, SENS, and VMD

Should you be buying Joint stock or one of its competitors? The main competitors of Joint include Edap Tms (EDAP), Design Therapeutics (DSGN), Sanara MedTech (SMTI), Codexis (CDXS), Immutep (IMMP), Akebia Therapeutics (AKBA), Monte Rosa Therapeutics (GLUE), AxoGen (AXGN), Senseonics (SENS), and Viemed Healthcare (VMD). These companies are all part of the "medical" sector.

Joint vs.

Edap Tms (NASDAQ:EDAP) and Joint (NASDAQ:JYNT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, community ranking, institutional ownership and media sentiment.

Edap Tms presently has a consensus target price of $14.00, suggesting a potential upside of 108.64%. Joint has a consensus target price of $22.00, suggesting a potential upside of 27.76%. Given Joint's stronger consensus rating and higher probable upside, equities research analysts clearly believe Edap Tms is more favorable than Joint.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edap Tms
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Joint
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50

Edap Tms received 65 more outperform votes than Joint when rated by MarketBeat users. Likewise, 62.84% of users gave Edap Tms an outperform vote while only 62.50% of users gave Joint an outperform vote.

CompanyUnderperformOutperform
Edap TmsOutperform Votes
345
62.84%
Underperform Votes
204
37.16%
JointOutperform Votes
280
62.50%
Underperform Votes
168
37.50%

Edap Tms has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, Joint has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500.

In the previous week, Edap Tms had 7 more articles in the media than Joint. MarketBeat recorded 8 mentions for Edap Tms and 1 mentions for Joint. Edap Tms' average media sentiment score of 0.00 beat Joint's score of -0.01 indicating that Joint is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Edap Tms
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Joint
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Joint has a net margin of -9.24% compared to Joint's net margin of -30.12%. Edap Tms' return on equity of 3.94% beat Joint's return on equity.

Company Net Margins Return on Equity Return on Assets
Edap Tms-30.12% -30.52% -19.64%
Joint -9.24%3.94%1.29%

Joint has higher revenue and earnings than Edap Tms. Joint is trading at a lower price-to-earnings ratio than Edap Tms, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edap Tms$65.42M3.81-$22.92M-$0.54-12.43
Joint$117.70M2.19-$9.75M-$0.75-22.96

62.7% of Edap Tms shares are held by institutional investors. Comparatively, 76.9% of Joint shares are held by institutional investors. 0.2% of Edap Tms shares are held by company insiders. Comparatively, 30.2% of Joint shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Joint beats Edap Tms on 9 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JYNT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

JYNT vs. The Competition

MetricJointPatent owners & lessors IndustryMedical SectorNASDAQ Exchange
Market Cap$257.85M$1.01B$5.24B$7.98B
Dividend YieldN/A4.91%44.56%3.91%
P/E Ratio-22.968.20139.1318.77
Price / Sales2.19167.232,371.9385.85
Price / Cash23.7213.5836.9831.98
Price / Book9.844.005.514.64
Net Income-$9.75M$32.06M$106.02M$217.28M
7 Day Performance4.74%2.47%1.42%2.90%
1 Month Performance41.38%10.18%4.97%6.66%
1 Year Performance16.59%-5.62%7.93%9.89%

Joint Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EDAP
Edap Tms
1.9423 of 5 stars
$6.89
-3.0%
$14.67
+112.9%
-35.5%$255.62M$65.42M-10.94307Analyst Forecast
News Coverage
DSGN
Design Therapeutics
2.4873 of 5 stars
$4.49
-1.3%
$6.60
+47.0%
-36.8%$253.64MN/A-4.2858Gap Up
SMTI
Sanara MedTech
0.9256 of 5 stars
$29.86
+2.0%
$44.00
+47.4%
-20.8%$257.48M$64.99M-57.42107Analyst Forecast
Analyst Revision
News Coverage
High Trading Volume
CDXS
Codexis
3.2907 of 5 stars
$3.65
+1.1%
$6.80
+86.3%
+35.2%$257.54M$70.14M-3.92174
IMMP
Immutep
0.8852 of 5 stars
$2.93
flat
$8.50
+190.1%
+21.8%$257.64M$3.50M0.002,021Analyst Forecast
Gap Up
AKBA
Akebia Therapeutics
3.9402 of 5 stars
$1.23
-4.7%
$5.00
+306.5%
+5.5%$257.81M$194.62M-5.35167Short Interest ↓
Gap Down
GLUE
Monte Rosa Therapeutics
0.7679 of 5 stars
$5.00
+1.0%
$11.00
+120.0%
-6.1%$252.55MN/A-1.98133News Coverage
AXGN
AxoGen
2.7119 of 5 stars
$5.77
-0.3%
$10.67
+84.9%
-34.4%$252.21M$159.01M-11.54426Short Interest ↑
News Coverage
Positive News
SENS
Senseonics
0.9056 of 5 stars
$0.49
+8.9%
$1.25
+155.7%
-35.2%$259.52M$22.39M-4.44132Analyst Forecast
VMD
Viemed Healthcare
2.4947 of 5 stars
$6.70
-5.0%
N/A-30.8%$260.09M$183.01M25.77996Positive News

Related Companies and Tools

This page (NASDAQ:JYNT) was last updated on 5/19/2024 by MarketBeat.com Staff

From Our Partners